Cidofovir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cidofovir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
46
Registered trials
20
Result records
11
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cidofovir can convert its Small molecule drug profile and UL30 x UL54 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cidofovir (query alias: cidofovir) |
|---|---|
| Modality / target | Small molecule drug; UL30 x UL54; UL30 inhibitors, UL54 inhibitors |
| Highest global status | Approved |
| Originator | Gilead Sciences, Inc. |
| Active developers | Marcan Pharmaceuticals, Inc. |
The MCP disease footprint includes Cytomegalovirus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04055142 | Phase 3 | Completed | 108 | % of patients with complete or partial regression of high grade anal intraepithelial neoplasia (HGAIN) at 10 weeks after end of treatment (with a permitted deviation of 4 weeks). |
| CTRI/2023/01/048654 | Phase 3 | Completed | 60 | Not disclosed |
| JPRN-jRCTs031240658 | Phase 2 | Recruiting | 20 | 研究組み入れから14日後の皮疹の見られる部位の皮膚検体PCR検査において、Ct値40以上となる患者の割合。 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
EFFICACY AND SAFETY OF CIDOFOVIR FOR ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT: A SINGLE-CENTER RETROSPECTIVE STUDY
Not Applicable; n=23; evaluation: Positive. Reported fields: Complete viral clearance = 9.0 Pts
Incidence, Patterns, and Outcomes of Adenovirus Infections in Patients Following Allogeneic Hematopoietic Cell Transplantation
Not Applicable; n=6053; evaluation: Positive. Reported fields: AdV infection rate = 31.0 % ( 10.0 - 65.0); AdV infection rate = 43.0 % ( 13.0 - 79.0); AdV infection rate = 14.0 % ( 12.0 - 15.0)
Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial
Phase 3; n=100; evaluation: Positive. Reported fields: Participant satisfaction = 4.77 mean ; Participant satisfaction = 5.1 mean ; Participant satisfaction = 5.6 mean
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cidofovir addresses Cytomegalovirus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 11 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: UL30 x UL54 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M | Discontinued | US$100.0M stated total |
| 2024-10-07 | Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. | Phase 2 | Financial terms not disclosed |
| 2022-12-19 | SymBio Pharmaceuticals has entered into a Sponsored Research Agreement with Tufts University to conduct joint research on the effectiveness of brincidofovir in a virus-infected brain tissue model. | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Green synthesis method of cidofovir”. The milestone feed surfaced a patent-application signal described as “Discovey of cidofovir for treating coronaviridae family of virus”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
